RJA
TBIO

Raymond James & Associates’s Translate Bio, Inc. Common Stock TBIO Stock Holding History

Raymond James & Associates’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,991
Closed -$89K – 3800
2019
Q4 		$89K Sell
10,991
-8,679
-44% -$80.1K ﹤0.01% 3486
2019
Q3 		$195K Buy
+19,670
New +$186K ﹤0.01% 3274

Other funds holding TBIO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James & Associates's TBIO Position: Q1 2020 in Review

Raymond James & Associates sold out of Translate Bio, Inc. Common Stock (TBIO) in Q1 2020, closing a stake of 10,991 shares — an estimated $89K sold.

Raymond James & Associates first reported a position in TBIO in Q3 2019 and held it in 2 quarters. The position peaked at $195K in Q3 2019. 74 funds tracked by Wall St. Rank hold TBIO as of Q1 2020.

  • Raymond James & Associates reported no remaining Translate Bio, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 10,991 Translate Bio, Inc. Common Stock shares in Q1 2020, an estimated $89K.
  • Raymond James & Associates first reported a position in Translate Bio, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Raymond James & Associates's Translate Bio, Inc. Common Stock position peaked at $195K in Q3 2019.
  • 74 funds tracked by Wall St. Rank held Translate Bio, Inc. Common Stock as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.